• HyperFluor™ 594 Goat Anti-Rabbit IgG: Illuminating ISG20 in

  2026-06-11

  Explore how HyperFluor™ 594 Goat Anti-Rabbit IgG (H+L) Antibody empowers advanced immunofluorescence and multiplexed detection of ISG20 in atherosclerosis studies. Gain actionable insights into assay optimization and the translational significance of immune gene profiling with this superior goat anti-rabbit IgG secondary antibody.

• Deferasirox Fe3+ Chelate: Mechanistic Insights for Translati

  2026-06-10

  Explore how Deferasirox Fe3+ chelate enables advanced modeling of iron overload and myeloid differentiation, integrating new mechanistic evidence and strategic protocol guidance for translational researchers.

• Pravastatin Sodium: Advanced Insights into Cholesterol Biosy

  2026-06-10

  Explore the molecular precision of Pravastatin sodium as a potent HMG-CoA reductase inhibitor. This article delivers novel analysis of transporter selectivity and practical assay design, distinguishing itself from standard protocol guides.

• Recombinant Human Oncostatin M: Mechanistic Insights & Preci

  2026-06-09

  Explore the advanced biological mechanisms and research advantages of Recombinant Human Oncostatin M (rh-Oncostatin M), with a focus on assay fidelity and novel mechanistic insight. This article uniquely connects cytokine biology with practical protocol decisions, offering an in-depth resource for precision cell signaling research.

• CHIR-99021 (CT99021): Beyond Pluripotency to Precision Signa

  2026-06-09

  Explore how CHIR-99021 (CT99021) enables precise, targeted modulation of stem cell fate by integrating pathway-level control with advanced protocol methodologies. This article uniquely bridges molecular mechanism with practical workflow optimization for cutting-edge stem cell research.

• LY2228820: Precision p38 MAP Kinase Inhibitor for Cancer and

  2026-06-08

  LY2228820 stands out as a highly selective, nanomolar-potent p38 MAP kinase inhibitor that empowers researchers to dissect inflammatory and oncogenic pathways with exceptional clarity. This article details real-world workflows, protocol enhancements, and practical troubleshooting strategies—equipping scientists to maximize reproducibility and translational impact in anti-inflammatory and cancer research.

• Anti-ROR1 Antibody (Zilovertamab): Applied Workflows & Optim

  2026-06-08

  Anti-ROR1 Antibody (Zilovertamab) from APExBIO sets a new benchmark for Wnt5a-induced ROR1 signaling inhibition in cancer and liver injury research. This guide offers actionable protocol parameters, troubleshooting insights, and evidence-based workflow enhancements that maximize reproducibility and specificity.

• CD40-STING-TRAF2 Competition Drives IRF4+ B Cell Activation

  2026-06-07

  This study uncovers how CD40 and STING competitively bind TRAF2 to regulate IRF4-mediated B cell activation within tertiary lymphoid structures (TLS) in esophageal squamous cell carcinoma (ESCC). The findings illuminate the molecular crosstalk essential for TLS-mediated antitumor immunity, offering new avenues for biomarker discovery and targeted therapy.

• Gasdermin C Drives Stemness and Immune Evasion in PDAC

  2026-06-06

  This study reveals that Gasdermin C (GSDMC) promotes stemness and immune evasion in pancreatic ductal adenocarcinoma (PDAC) through a unique, pyroptosis-independent mechanism. By dissecting the nuclear actions of GSDMC fragments, the research identifies new molecular targets to enhance therapeutic responses in PDAC.

• STING Agonist-1 in TLS-Driven Cancer Immunity: Mechanisms &

  2026-06-05

  Explore the latest insights on STING agonist-1 and its pivotal role in tertiary lymphoid structure (TLS)-mediated antitumor immunity. This in-depth article deciphers new mechanistic findings, protocol nuances, and best practices for advanced immunology research.

• Capsazepine: TRPV1 Ion Channel Antagonist for Pain Pathway R

  2026-06-05

  Capsazepine offers researchers reliable, selective inhibition of TRPV1 ion channels, making it a preferred tool for dissecting nociceptive and apoptosis mechanisms. Optimize your pain and cancer research workflows with precise protocol parameters and troubleshooting strategies that leverage Capsazepine’s unique pharmacology.

• Decitabine Priming Enhances Anti–PD-1 Efficacy via CD8+ Prog

  2026-06-04

  Li et al. reveal that low-dose decitabine priming fundamentally boosts the antitumor efficacy of PD-1 immune checkpoint blockade by expanding and sustaining CD8+ progenitor exhausted T cells in tumor models. This epigenetic modulation strategy reshapes T cell function and opens new avenues for improving immunotherapy responses.

• Decoding Ribosomal Stress: Prestained Protein Marker in Next

  2026-06-04

  Explore how the Prestained Protein Marker (Triple color, EDTA free) empowers advanced SDS-PAGE and Western blotting, uniquely linking ribotoxic stress research with practical assay optimization. Discover scientific insights and protocol strategies not found in standard guides.

• Moxidectin: Redefining Macrocyclic Lactone Anthelmintic Hori

  2026-06-03

  This article explores the mechanistic and translational frontiers of moxidectin, a macrocyclic lactone anthelmintic with dual roles in veterinary antiparasitic control and emerging antifungal synergy. By bridging recent mechanistic discoveries with strategic guidance for translational researchers, we position APExBIO’s high-purity moxidectin as a catalyst for cross-domain innovation.

• Deferasirox Alters Myeloid Differentiation via NF-κB and ROS

  2026-06-03

  This study demonstrates that Deferasirox, a clinical iron chelator, modulates myeloid cell differentiation by altering mitochondrial ROS and NF-κB activity in both human and murine models. The findings offer mechanistic insight into hematologic improvements seen in iron overload disorders and highlight stage-dependent effects on progenitor versus mature myeloid cells.

451 records 15/31 page Previous Next First page 上5页 1112131415 下5页 Last page